Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. - Wikidata - awgldk - TriplyDB

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.

http://www.wikidata.org/entity/Q38418892

about

Superior Orbital Fissure Syndrome and Ophthalmoplegia Caused by Varicella Zoster Virus with No Skin Eruption in a Patient Treated with Tumor Necrosis Alpha Inhibitor.Herpes Zoster Meningitis Complicating Combined Tocilizumab and Cyclosporine Therapy for Adult-Onset Still's Disease.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.The role of IL-6 in host defence against infections: immunobiology and clinical implications.Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.Asthma status is an independent risk factor for herpes zoster in children: a population-based cohort study.Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia.Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service - Sample cohort database.Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Studies with herpes zoster vaccines in immune compromised patients.2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges.Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.

P2860

Q36291639-C8D2B2F2-1D40-4183-BF12-855BC07F49BD Q36764586-FE373366-2071-4F29-90DF-760C2066C69D Q37484842-534FF759-0840-49FD-B1F1-74EDF247BF94 Q38725223-1B7F930D-5D0C-4697-BD9D-2082C09847B5 Q38827889-0FAA0FC7-30BE-4122-BBBE-79C7BE49D39F Q38837769-BF3C7E5B-A6A3-4824-9138-14B65E74DABF Q38884360-B5EC37AA-881D-4693-ABC4-C9B92900DE3C Q38947199-DA3120C7-C4B8-4372-BC50-9597EC12514E Q39013188-39545CB4-02B9-4354-86B2-155E128CE679 Q39822865-25B8A847-7ACB-4032-90FF-228162198F50 Q40175407-78A015F3-4EA4-4283-8768-955EC9E753D1 Q40184103-F4B18A43-7D6A-454E-B3BF-FE4A645972A3 Q41912068-A753191E-0436-4D48-A648-3692A92A3EDA Q45324979-81C46DA5-5EB7-4573-BC62-346E45248461 Q47605669-F44D210B-0C41-4D1F-A3A7-CA66447EBE98 Q48089791-8E10C029-2C43-4964-99E4-AAA7CDBED882 Q54508929-002C5400-F52B-4261-8EBB-9DCBB3739DFC Q55393981-4CEE8577-78C8-4256-A8DA-3CBF0D42E571

P2860

Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.

http://www.wikidata.org/entity/Q38418892

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Risks of herpes zoster in pati ...... gic disease-modifying therapy.

@en

type

label

Risks of herpes zoster in pati ...... gic disease-modifying therapy.

@en

prefLabel

Risks of herpes zoster in pati ...... gic disease-modifying therapy.

@en

P1433

Q38418892-FB0375DA-BC92-43EF-835D-C2123F8E58E9

P1476

Q38418892-E5575A00-AE68-43FF-A6FF-1811F62E0768

P2093

Q38418892-1926A7C4-3233-448C-89A6-B1A8395D6423

Q38418892-33138645-51F7-4D82-9830-C8584D7E835E

Q38418892-4B397005-1DCA-4386-8645-1EEC426F4381

Q38418892-512CD82A-C673-485B-B78C-A60A2008B604

Q38418892-5A2A7E46-C14F-4834-98C4-72762D12788D

Q38418892-73D565C8-15A5-480A-BE56-17AFB703A069

Q38418892-9F582D42-28AB-4711-B9CF-5C7E4E41ED27

Q38418892-A16F29B0-95FC-44BD-82AF-B71F4270BD13

Q38418892-B4708656-6CBD-4143-ACA2-F6023C05250F

Q38418892-C49C5679-289D-40EA-A381-C4BA97322311

P2860

Q38418892-025DD16D-1181-4B24-9BB4-AA7D69456A93

Q38418892-175FC835-2FBF-415F-B746-C5E6CB4DF168

Q38418892-32082843-45F4-48A6-BB40-76B49870F070

Q38418892-330FD7B2-AF59-43B2-ACD9-AF0ECA746206

Q38418892-35B7A954-67B0-4C40-BF87-5A80EBDCA669

Q38418892-57B82DD6-3428-4801-8115-9398E705ED80

Q38418892-5F7DA64F-377E-469C-A1AF-8D720F57ACE7

Q38418892-61FE4873-9B42-4067-8559-400F0C640370

Q38418892-76284158-5422-4ADC-BD43-DA642C794180

Q38418892-779D6E4F-A7BB-48BB-B8CC-596AF48FA980

P304

Q38418892-CF231E9B-020D-4CEF-81E6-1ABEAE53F836

P31

Q38418892-15F19397-0B7E-4046-81C7-2705050B52EE

P356

Q38418892-E4A3F54E-6B3D-4311-BADB-B15C3B6AF17E

P433

Q38418892-AEEAEAA0-9723-4495-A311-2D5505D3F12B

P478

Q38418892-47CC1261-23C7-4E34-95F4-7A40DCFE8DC6

P577

Q38418892-92FE313C-18B8-4E7D-A854-A8AF36543082

P698

Q38418892-B95356F0-44AC-4304-8715-41916206C5F0

P932

Q38418892-3D02A25D-01CB-4F81-8DD3-96EF33287770

P356

P1433

Arthritis Care and Research

P1476

Risks of herpes zoster in pati ...... gic disease-modifying therapy.

@en

P2093

Elizabeth Delzell

http://www.w3.org/2001/XMLSchema#string

Emily B Levitan

http://www.w3.org/2001/XMLSchema#string

Fenglong Xie

http://www.w3.org/2001/XMLSchema#string

Huifeng Yun

http://www.w3.org/2001/XMLSchema#string

James D Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

John W Baddley

http://www.w3.org/2001/XMLSchema#string

Kenneth G Saag

http://www.w3.org/2001/XMLSchema#string

Kevin Winthrop

http://www.w3.org/2001/XMLSchema#string

Lang Chen

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

The incidence of herpes zoster

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

More accurate racial and ethnic codes for Medicare administrative data

Validation of rheumatoid arthritis diagnoses in health care utilization data

Clinical practice: Herpes zoster

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Clinical practice. Herpes zoster.

Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.

P304

731-736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.22470

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25201241

http://www.w3.org/2001/XMLSchema#string

P932

5765980

http://www.w3.org/2001/XMLSchema#string